These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole derivatives. Chimenti F; Maccioni E; Secci D; Bolasco A; Chimenti P; Granese A; Befani O; Turini P; Alcaro S; Ortuso F; Cirilli R; La Torre F; Cardia MC; Distinto S J Med Chem; 2005 Nov; 48(23):7113-22. PubMed ID: 16279769 [TBL] [Abstract][Full Text] [Related]
7. Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Karuppasamy M; Mahapatra M; Yabanoglu S; Ucar G; Sinha BN; Basu A; Mishra N; Sharon A; Kulandaivelu U; Jayaprakash V Bioorg Med Chem; 2010 Mar; 18(5):1875-81. PubMed ID: 20149663 [TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors. Chimenti F; Fioravanti R; Bolasco A; Manna F; Chimenti P; Secci D; Befani O; Turini P; Ortuso F; Alcaro S J Med Chem; 2007 Feb; 50(3):425-8. PubMed ID: 17266193 [TBL] [Abstract][Full Text] [Related]
9. Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase. Maccioni E; Alcaro S; Orallo F; Cardia MC; Distinto S; Costa G; Yanez M; Sanna ML; Vigo S; Meleddu R; Secci D Eur J Med Chem; 2010 Oct; 45(10):4490-8. PubMed ID: 20702005 [TBL] [Abstract][Full Text] [Related]
10. Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies. Sahoo A; Yabanoglu S; Sinha BN; Ucar G; Basu A; Jayaprakash V Bioorg Med Chem Lett; 2010 Jan; 20(1):132-6. PubMed ID: 19945874 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of human monoamine oxidase inhibitory activities of some 3,5-diaryl-N-substituted-4,5-dihydro-1H-pyrazole-1-carbothioamide derivatives. Sentürk K; Tan OU; Ciftçi SY; Uçar G; Palaska E Arch Pharm (Weinheim); 2012 Sep; 345(9):695-702. PubMed ID: 22674756 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors. Fioravanti R; Bolasco A; Manna F; Rossi F; Orallo F; Yáñez M; Vitali A; Ortuso F; Alcaro S Bioorg Med Chem Lett; 2010 Nov; 20(22):6479-82. PubMed ID: 20934874 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors. Gökhan-Kelekçi N; Simşek OO; Ercan A; Yelekçi K; Sahin ZS; Işik S; Uçar G; Bilgin AA Bioorg Med Chem; 2009 Sep; 17(18):6761-72. PubMed ID: 19682910 [TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives. Vishnu Nayak B; Ciftci-Yabanoglu S; Jadav SS; Jagrat M; Sinha BN; Ucar G; Jayaprakash V Eur J Med Chem; 2013 Nov; 69():762-7. PubMed ID: 24099995 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of some novel hydrazone and 2-pyrazoline derivatives: monoamine oxidase inhibitory activities and docking studies. Evranos-Aksöz B; Yabanoğlu-Çiftçi S; Uçar G; Yelekçi K; Ertan R Bioorg Med Chem Lett; 2014 Aug; 24(15):3278-84. PubMed ID: 24986657 [TBL] [Abstract][Full Text] [Related]
16. Chalcones: a valid scaffold for monoamine oxidases inhibitors. Chimenti F; Fioravanti R; Bolasco A; Chimenti P; Secci D; Rossi F; Yáñez M; Orallo F; Ortuso F; Alcaro S J Med Chem; 2009 May; 52(9):2818-24. PubMed ID: 19378991 [TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. Pisani L; Muncipinto G; Miscioscia TF; Nicolotti O; Leonetti F; Catto M; Caccia C; Salvati P; Soto-Otero R; Mendez-Alvarez E; Passeleu C; Carotti A J Med Chem; 2009 Nov; 52(21):6685-706. PubMed ID: 19810674 [TBL] [Abstract][Full Text] [Related]
18. A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Gökhan-Kelekçi N; Yabanoğlu S; Küpeli E; Salgin U; Ozgen O; Uçar G; Yeşilada E; Kendi E; Yeşilada A; Bilgin AA Bioorg Med Chem; 2007 Sep; 15(17):5775-86. PubMed ID: 17611112 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Chimenti F; Bolasco A; Manna F; Secci D; Chimenti P; Granese A; Befani O; Turini P; Cirilli R; La Torre F; Alcaro S; Ortuso F; Langer T Curr Med Chem; 2006; 13(12):1411-28. PubMed ID: 16719786 [TBL] [Abstract][Full Text] [Related]
20. Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation. Mishra N; Sasmal D Bioorg Med Chem Lett; 2011 Apr; 21(7):1969-73. PubMed ID: 21377879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]